[go: up one dir, main page]

ZA200106488B - N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance. - Google Patents

N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance.

Info

Publication number
ZA200106488B
ZA200106488B ZA200106488A ZA200106488A ZA200106488B ZA 200106488 B ZA200106488 B ZA 200106488B ZA 200106488 A ZA200106488 A ZA 200106488A ZA 200106488 A ZA200106488 A ZA 200106488A ZA 200106488 B ZA200106488 B ZA 200106488B
Authority
ZA
South Africa
Prior art keywords
insulin resistance
piperidinyl
propoxy
pyridine
hydroxy
Prior art date
Application number
ZA200106488A
Other languages
English (en)
Inventor
Maria Kuerthy
Katalin Biro
Karoly Nagy
Laszlo Uroegdi
Zita Csakai
Jenoe Szilbereky
Tamas Mogyorosi
Magdolna Toeroek
Andras Komaromi
Ede Marvanyos
Mihaly Barabas
Mihalyne Kardos
Zoltan Nagy
Laszlo Koranyi
Melinda Nagy
Original Assignee
Biorex Kutato Fejlesztoe Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutato Fejlesztoe Kft filed Critical Biorex Kutato Fejlesztoe Kft
Publication of ZA200106488B publication Critical patent/ZA200106488B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200106488A 1999-02-26 2001-08-07 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance. ZA200106488B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9900475A HUP9900475D0 (en) 1999-02-26 1999-02-26 O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component

Publications (1)

Publication Number Publication Date
ZA200106488B true ZA200106488B (en) 2002-08-07

Family

ID=90014224

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200106488A ZA200106488B (en) 1999-02-26 2001-08-07 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance.

Country Status (27)

Country Link
US (1) US6649628B1 (ru)
EP (1) EP1163224B1 (ru)
JP (1) JP4689838B2 (ru)
KR (1) KR100676124B1 (ru)
AT (1) ATE237590T1 (ru)
AU (1) AU779096B2 (ru)
BG (1) BG65178B1 (ru)
BR (1) BR0008969A (ru)
CA (1) CA2360451C (ru)
CZ (1) CZ297386B6 (ru)
DE (1) DE60002187T2 (ru)
DK (1) DK1163224T3 (ru)
EE (1) EE04961B1 (ru)
ES (1) ES2193055T3 (ru)
HR (1) HRP20010584B1 (ru)
HU (1) HUP9900475D0 (ru)
IL (2) IL144866A0 (ru)
NO (1) NO319793B1 (ru)
PL (1) PL197692B1 (ru)
PT (1) PT1163224E (ru)
RS (1) RS50083B (ru)
RU (1) RU2250901C2 (ru)
SI (1) SI1163224T1 (ru)
SK (1) SK287063B6 (ru)
UA (1) UA72495C2 (ru)
WO (1) WO2000050403A1 (ru)
ZA (1) ZA200106488B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
CA2471752A1 (en) * 2002-01-11 2003-07-17 Biorex Kutato Es Fejlesztoe Rt. Carboxamidine derivatives and their use in the treatment of vascular diseases
HUP0303584A3 (en) 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
TW200831479A (en) * 2006-09-26 2008-08-01 Cytrx Corp Pharmaceutical compositions and methods for treating diseases
DK2484371T3 (en) 2008-06-26 2015-03-02 Orphazyme Aps The use of Hsp70 as a regulator of enzymatic activity
CA2743782A1 (en) 2008-11-18 2010-05-27 Santen Pharmaceutical Co., Ltd. Therapeutic agent for chorioretinal degenerative disease containing pyridine-3-carbaldehyde o-(piperidin-1-yl-propyl)-oxime derivative as active ingredient
DK2646044T3 (da) 2010-11-30 2019-11-25 Orphazyme As Metoder til at øge den intracellulære aktivitet af Hsp70
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
ES2691981T3 (es) * 2012-09-06 2018-11-29 Mcpharma Biotech Inc. Tratamiento de la diarrea y de la diarrea post-destete con almidón resistente de patata
DK2896269T4 (da) 2012-09-14 2020-08-31 Saint Gobain Rude med et elektrisk forbindelseselement
WO2015015248A1 (en) * 2013-07-30 2015-02-05 Debreceni Egyetem 67% The use of compounds showing heat shock protein (hsp) co-inducing properties to enhance the insulin sensitizing effect in the treatment of type 2 diabetes
PT3193840T (pt) 2014-09-15 2021-08-10 Orphazyme Aps Formulação de arimoclomol
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
JP6818045B2 (ja) 2016-04-29 2021-01-20 オーファザイム エー／エス グルコセレブロシダーゼ関連障害を治療するためのアリモクロモル
MX2019013835A (es) 2017-05-24 2020-07-14 Orphazyme As Inductores de proteinas de choque termico y trastornos frontotemporales.
AU2019276048A1 (en) 2018-05-28 2021-01-21 Zevra Denmark A/S Hsp70 protein levels in PBMC samples as biomarker for disease
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
WO2021116487A1 (en) 2019-12-13 2021-06-17 Som Innovation Biotech, S.A. Compounds for use in the treatment of niemann-pick c disease
CN116075305A (zh) 2020-06-24 2023-05-05 柯姆药物丹麦股份公司 用于治疗戈谢病的阿瑞洛莫
MX2023005954A (es) 2020-11-19 2023-09-04 Zevra Denmark As Procesos para preparar citrato de arimoclomol e intermediarios del mismo.
US20240115558A1 (en) 2020-12-24 2024-04-11 Zevra Denmark A/S Arimoclomol for the treatment of niemann pick disease, type c, in patients with er type missense mutations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUT78138A (hu) * 1995-12-22 2000-09-28 BIOREX Kutató és Fejlesztő Rt Hidroximsavszármazékot tartalmazó készítmény a növénytermesztés elősegítésére és alkalmazása
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HU220971B1 (hu) * 1997-04-03 2002-07-29 BIOREX Kutató és Fejlesztő Rt. Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké

Also Published As

Publication number Publication date
AU779096B2 (en) 2005-01-06
EP1163224A1 (en) 2001-12-19
CZ297386B6 (cs) 2006-11-15
RS50083B (sr) 2009-01-22
YU60301A (sh) 2004-05-12
EE04961B1 (et) 2008-02-15
BG105837A (en) 2002-03-29
HRP20010584A2 (en) 2002-08-31
UA72495C2 (ru) 2005-03-15
KR20010102410A (ko) 2001-11-15
US6649628B1 (en) 2003-11-18
KR100676124B1 (ko) 2007-01-31
SK287063B6 (sk) 2009-10-07
NO20014103D0 (no) 2001-08-23
CZ20013053A3 (cs) 2002-01-16
EP1163224B1 (en) 2003-04-16
HUP9900475D0 (en) 1999-04-28
RU2250901C2 (ru) 2005-04-27
HRP20010584B1 (en) 2010-08-31
CA2360451A1 (en) 2000-08-31
DE60002187T2 (de) 2003-12-11
NO20014103L (no) 2001-10-22
ES2193055T3 (es) 2003-11-01
PL197692B1 (pl) 2008-04-30
JP4689838B2 (ja) 2011-05-25
PL350915A1 (en) 2003-02-10
BG65178B1 (bg) 2007-05-31
NO319793B1 (no) 2005-09-12
IL144866A0 (en) 2002-06-30
IL144866A (en) 2007-07-04
DK1163224T3 (da) 2003-08-04
DE60002187D1 (de) 2003-05-22
PT1163224E (pt) 2003-07-31
CA2360451C (en) 2011-01-04
BR0008969A (pt) 2001-11-27
SK11582001A3 (sk) 2001-12-03
SI1163224T1 (en) 2003-08-31
EE200100447A (et) 2002-12-16
WO2000050403A1 (en) 2000-08-31
AU3182400A (en) 2000-09-14
JP2002537384A (ja) 2002-11-05
ATE237590T1 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
IL144866A0 (en) N- [2-hydroxy-3- (1-piperidinyl) propoxy] pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance
GB0223038D0 (en) Therapeutic compounds
GB0225474D0 (en) Therapeutic agents
CA2332521A1 (en) Pharmaceutical composition for treating or preventing sleep disorders
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
DE59410052D1 (de) Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids
CA2361834A1 (en) Offset ablation profiles for treatment of irregular astigmatism
NZ504258A (en) Exendin 3 and 4 agonist compounds for the treatment of diabetes
RU2001126126A (ru) N-[2-гидрокси-3-(1-пиперидинил)пропокси]пиридин-1-оксид-3-карбоксиимидоилхлорид и его применение при лечении невосприимчивости к инсулину
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
SE0102147D0 (sv) New methods
UA72927C2 (ru) Композиция для лечения рака печени, содержащая доцетаксель
RS52011B (sr) Nova primena derivata taksoida
BG105204A (en) Salts of paroxetine
MY129832A (en) Substituted thiophenes, processes for their preparation, their use as medicament or diagnostic and medicament comprising them
AU3600199A (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
TR200101980T2 (tr) Arilalkanoil türevleri, bunların preparasyon işlemleri
WO1999051216A3 (en) 3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists
IL142247A0 (en) Method of treating sickle cell disease and thalassemia
TW200503999A (en) Therapeutic agents
PL355113A1 (en) Novel fusidic acid derivatives
BR9609932A (pt) Uso de derivados de prostano e a combinação dos mesmos com antibióticos no tratamento das infecções bacterianas
GEP20043220B (en) S-Nitrosothiols as Agents for The Treatment of Circulatory Dysfunctions
MXPA05014081A (es) Derivados de benzofurano y su uso en el tratamiento de infecciones microbianas.